| Hospice Of The Angels Inc 4959 Palo Verde Street Suite 110b, Montclair, CA, 91763 | |
| (626) 780-6131 |
News Archive
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Stroke survivors with higher scores on widely used outcome measures are more likely to be discharged home from the hospital, while those with lower scores are more likely to go to a rehabilitation or nursing care facility, reports a paper in the January issue of The Journal of Neurologic Physical Therapy.
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
To support the aims of the EU's Year of Air, DESSO, a leading European carpet and sports pitches manufacturer is launching its own campaign, 'The Great Indoors' to raise awareness of the continued dangers of bad indoor air quality and to demonstrate what business and innovation can do to combat the problem.
› Verified 2 days ago
| Name | Hospice Of The Angels Inc |
|---|---|
| Location | 4959 Palo Verde Street Suite 110b, Montclair, California |
| Hospice ID | 551615 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 460 |
News Archive
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Stroke survivors with higher scores on widely used outcome measures are more likely to be discharged home from the hospital, while those with lower scores are more likely to go to a rehabilitation or nursing care facility, reports a paper in the January issue of The Journal of Neurologic Physical Therapy.
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
To support the aims of the EU's Year of Air, DESSO, a leading European carpet and sports pitches manufacturer is launching its own campaign, 'The Great Indoors' to raise awareness of the continued dangers of bad indoor air quality and to demonstrate what business and innovation can do to combat the problem.
› Verified 2 days ago
| NPI Number | 1801181813 |
| Organization Name | Hospice Of The Angels, Inc. |
| Address | 4959 Palo Verde St Montclair, California, 91763 |
| Phone Number | (909)624-3838 |
News Archive
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Stroke survivors with higher scores on widely used outcome measures are more likely to be discharged home from the hospital, while those with lower scores are more likely to go to a rehabilitation or nursing care facility, reports a paper in the January issue of The Journal of Neurologic Physical Therapy.
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
To support the aims of the EU's Year of Air, DESSO, a leading European carpet and sports pitches manufacturer is launching its own campaign, 'The Great Indoors' to raise awareness of the continued dangers of bad indoor air quality and to demonstrate what business and innovation can do to combat the problem.
› Verified 2 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 96.7 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 98.7 | 97.3 |
| Patients who got timely treatment for shortness of breath | 100.0 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Stroke survivors with higher scores on widely used outcome measures are more likely to be discharged home from the hospital, while those with lower scores are more likely to go to a rehabilitation or nursing care facility, reports a paper in the January issue of The Journal of Neurologic Physical Therapy.
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
To support the aims of the EU's Year of Air, DESSO, a leading European carpet and sports pitches manufacturer is launching its own campaign, 'The Great Indoors' to raise awareness of the continued dangers of bad indoor air quality and to demonstrate what business and innovation can do to combat the problem.
› Verified 2 days ago
| Home Health Aides | 2.5 |
| Counselors | 1 |
| Licensed Practical or Vocational Nurses | 5 |
| Medical Social Workers | 1 |
| Physicians | 1 |
| Registered Nurses | 4 |
| Other Personnel | 2 |
| Total Employees | 16.5 |
|---|
News Archive
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Stroke survivors with higher scores on widely used outcome measures are more likely to be discharged home from the hospital, while those with lower scores are more likely to go to a rehabilitation or nursing care facility, reports a paper in the January issue of The Journal of Neurologic Physical Therapy.
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
To support the aims of the EU's Year of Air, DESSO, a leading European carpet and sports pitches manufacturer is launching its own campaign, 'The Great Indoors' to raise awareness of the continued dangers of bad indoor air quality and to demonstrate what business and innovation can do to combat the problem.
› Verified 2 days ago
| Others | 2 |
| Total Volunteers | 2 |
|---|
News Archive
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Stroke survivors with higher scores on widely used outcome measures are more likely to be discharged home from the hospital, while those with lower scores are more likely to go to a rehabilitation or nursing care facility, reports a paper in the January issue of The Journal of Neurologic Physical Therapy.
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
To support the aims of the EU's Year of Air, DESSO, a leading European carpet and sports pitches manufacturer is launching its own campaign, 'The Great Indoors' to raise awareness of the continued dangers of bad indoor air quality and to demonstrate what business and innovation can do to combat the problem.
› Verified 2 days ago
| Qualcare Hospice Inc Location: 4959 Palo Verde Street, Suite 106c, Montclair, California, 91763 Phone: (626) 780-6131 |
| Divine Mercy Hospice Inc Location: 5589 Brook Street, Unit B, Montclair, California, 91763 Phone: (626) 780-6131 |
| Hospice Of The Angels Inc Location: 4959 Palo Verde Street Suite 110b, Montclair, California, 91763 Phone: (626) 780-6131 |
| Angels On Earth Hospice Location: 4959 Palo Verde Street Suite 202-a, Montclair, California, 91763 Phone: (626) 780-6131 |